Author Guidelines

CDK (Cermin Dunia Kedokteran) accepts manuscripts that discuss various aspects of medicine, pharmacy, and health, including research studies, systematic reviews, meta-analyses, case reports, and literature reviews. Submitted manuscripts must be intended for publication in CDK (i.e., not published in other journals); if they have been presented or discussed at a scientific meeting, please provide the meeting name, location, and date.
 
GENERAL GUIDELINES
Files in Ms. Word format. Starting in May 2026, CDK will accept only manuscripts written in English that follow proper structure and grammar. Manuscripts should be between 2,000 and 4,000 words (from abstract to conclusion) on A4 paper (210 mm x 297 mm), written using MS Word, Times New Roman font size 12 pt, single-spaced, justified. Manuscripts will be checked using the Turnitin application, and the maximum similarity index is 25%.
 
Research, systematic review, meta-analyses, and evidence-based case report manuscripts are organized into 5 subheadings: Introduction, Methods, Results, Discussion, and Conclusion. Case report manuscripts are organized into 4 subheadings: Introduction, Case, Discussion, and Conclusion. Literature reviews are organized into several subsections: Introduction, Methods (if applicable), Discussion, and Conclusion. The author may adjust the subsections as needed.
The manuscript templates: https://bit.ly/4hfapVo

AUTHOR NAME AND INSTITUTION
Author(s) Name: Listed in full (no abbreviations), with an asterisk next to the author's name.
Author Institution: Information about the institution/faculty/institute where the author works, including the name of the city and country.

ABSTRACT AND KEYWORDS

Each manuscript must be accompanied by an abstract in English, along with 4–6 keywords listed in alphabetical order. The abstract should be 150–300 words.
 
The abstract should be written in 1 (one) paragraph, in the following format:
- Evidence-based research/systematic reviews/meta-analyses/case reports: structured using the introduction, methods, results, conclusion (IMRAD) format
- Case reports: structured using the introduction, case, discussion, conclusion format
- Literature reviews: no specific format is required, but they must include the key points of the manuscript’s content

Tables/Graphs/Figures/Scheme

All tables, graphs, figures, and diagrams must be numbered sequentially using Arabic numerals (1, 2, 3, not A, B, C), and must be cited in the text. All tables, graphs, figures, and diagrams that support the content of the manuscript may be submitted separately in JPG format (they must be proportional and have good resolution, with a minimum resolution of 300 dpi at their original size). However, they must still appear in the manuscript.
 
Captions for figures/tables/graphs/diagrams must be written in 11-point Times New Roman font, with single spacing. Captions for figures and graphs must be placed below them, while table captions must be placed above them. Abbreviations used in tables, graphs, figures, or diagrams may have their full forms listed in the “Notes” section below the table, graph, figure, or diagram. Include citations for tables, graphs, figures, or diagrams; if they are personal documentation, include the author’s name (e.g., Documentation by…).

Citations
Citations in articles are written using Arabic numerals and are numbered in the order in which they appear in the article. Numbers are written in superscript format without parentheses, for example, “1”. References are written after punctuation marks, for example: 1–3.

Manuscript Declaration

After the Conclusion, include the following statements:

Ethics Statement

If the study involves human or animal subjects, approval from the appropriate ethics committee must be provided, including the registration number or official reference.

Informed Consent

If the study involves human participants, authors must state that informed consent to participate was obtained from all participants in accordance with applicable ethical requirements.

Consent for Publication

If the study includes institutional names, personal data, or identifiable images of individuals, authors must state that consent for publication was obtained from the institution, the patient or legal guardian. If not applicable, this should be explicitly declared.

Funding

Sources of funding or grants supporting the study must be clearly stated. If the study did not receive any financial support, this should be explicitly declared.

Author Contribution

For example: (Author name(s) or initial) contributed to the conception and design, collected data, and wrote the first draft of the manuscript. All authors reviewed and approved the manuscript.

Conflict of Interest

Authors must clearly declare whether any conflicts of interest exist, whether financial or non-financial. If no conflicts of interest exist, authors should state that they have no conflicts of interest.

Declaration on the Use of Artificial Intelligence (AI)

If artificial intelligence was used during the conduct of the study or the preparation of the manuscript, its use should be described in detail, such as for data analysis, language editing, or draft preparation. Authors must affirm that the entire content of the manuscript has been reviewed, verified, and approved by the authors, and that full responsibility for the content remains with the authors.

Acknowledgments (optional)

List individuals or organizations that contributed to the study but do not qualify for authorship, such as supporting institutions, research assistants, or language editors, where available.

 

References
References are arranged according to the Vancouver rules. References are numbered in order of appearance in the article. If there are six or fewer authors, list them all; if there are seven or more, list the first six and add “et al.”

There must be at least 15 references, published within the last 10 years. Try to include more primary references (for example from journals, at least 80%) than secondary references. For each reference, include the doi (digital object identifier) or PMID (PubMed identifier), if available.

Example of reference format according to Vancouver rules:
Journal
•    Standard

  1. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008; 36(7646):701−4. doi: 10.1136/bmj.39497.500903.25.
  2. Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1−2):40−6. doi: 10.1016/s0006-8993(02)02445-9.

•    Organization as Author

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241−8. doi: 10.1001/archneur.62.2.241.

  • No Author Name

      21st century heart solution may have a sting in the tail. BMJ. 2002 Jul 27;325(7357):184. PMID: 12142303.

  • Volume with Supplements

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42(Suppl 2):S93−9. doi: 10.1046/j.1526-4610.42.s2.7.x.

  • Edition with Supplements

Glauser TA. Integrating clinical trial data into clinical practice. Neurology 2002;58(12 Suppl 7):6−12. doi: 10.1212/wnl.58.12_suppl_7.s6.

  • Electronic Journal

Alwan A, Maclean E. Monitoring and evaluation of health systems strengthening: a practical approach. Health Policy Plan [Internet]. 2020 [cited 2025 Jul 24];35(6):681–4. Available from: https://academic.oup.com/heapol/article/35/6/681/5855567.

Book

  • Sole Author/Editor Tunggal

Hoppert M. Microscopic techniques in biotechnology. Weinheim: Wiley-VCH; 2003.

  • More Than One Author/Editor

Gilstrap LC, Cunningham FG, Van Dorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

  • Edition with Volume

Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Wintrobes clinical hematology. 9th ed. Vol 2. Philadelphia: Lea & Febiger; 1993.

  • Chapters in a Book

Ford HL, Sclafani RA, DeGregori J. Cell cycle regulatory cascades. In: Stein GS, Pardee AB, editors. Cell cycle and growth control: biomolecular regulation and cancer. 2nd ed. Hoboken (NJ): Wiley-Liss; 2004. p. 42−67.

Conference Proceedings

Harnden P, Joe JK, Jones WG, editors. Germ cell tumours V: Proceedings of the 5th Germ Cell Tumour conference; 2001 Sep 13−15; Leeds, UK. New York: Springer; 2002.

Conference Paper

Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming: EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 35−; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182−9.

 

MANUSCRIPT SUBMISSION
Manuscripts are sent to the editor in softcopy to this website.

CDK Editorial
Jl. Letjen Suprapto Kav. 4 Cempaka Putih, Jakarta 10510
E-mail: cdk@kalbe.co.id
Phone: (+6221) 42873888 - 89 ext. 2025

All statements in the manuscript are the responsibility of the author. The editorial board reserves the right to edit the wording without altering the content. Unpublished manuscripts will be returned to the author upon request. Given that CDK is currently accessible via the internet (online), published manuscripts will be more easily downloaded and utilized by a wider audience. Further correspondence will be conducted through the cdkjournal website.

The writings in this journal are the views/opinions of each author and do not necessarily represent the views or policies of the agency/institution where the author works.